PolyPeptide Group AG (XSWX:PPGN) Current Deferred Taxes Liabilities: CHF0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
72 GF Score
Price CHF44.00
GF Value CHF35.19
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Current Deferred Taxes Liabilities?

PolyPeptide Group AG XSWX:PPGN 72 Current Deferred Taxes Liabilities is CHF0.0 Mil as of Jun. 2026. GuruFocus rates XSWX:PPGN with a GF Score™ of 72/100 and a GF Value™ of CHF35.19 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

PolyPeptide Group AG's current deferred tax liabilities for the quarter that ended in Jun. 2026 was CHF0.0 Mil.

PolyPeptide Group AG Current Deferred Taxes Liabilities Related Terms

PolyPeptide Group AG Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Current Deferred Taxes Liabilities Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:PPGN
72GF Score
PolyPeptide Group AG XSWX:PPGN
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of CHF0.0 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Current Deferred Taxes Liabilities of CHF0.0 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Current Deferred Taxes Liabilities too high?
PolyPeptide Group AG's current Current Deferred Taxes Liabilities is CHF0.0 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Current Deferred Taxes Liabilities compare to ZTS and UTHR?
PolyPeptide Group AG's Current Deferred Taxes Liabilities of CHF0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Drug Manufacturers company?
A good Current Deferred Taxes Liabilities depends on the Drug Manufacturers industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Current Deferred Taxes Liabilities is CHF0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF35.19, compared to a current price of CHF44.00 — trading 25% above its estimated fair value. The current Current Deferred Taxes Liabilities is CHF0.0 Mil. PolyPeptide Group AG's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Current Deferred Taxes Liabilities is CHF0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF44.00 is trading 25% above its estimated GF Value™ of CHF35.19. GuruFocus considers PolyPeptide Group AG to be Modestly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Current Deferred Taxes Liabilities: CHF0.0 Mil
  • GF Value™: CHF35.19 vs. price of CHF44.00 (25% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
72GF Score

Get the complete analysis for XSWX:PPGN

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF44.00
Price
CHF35.19
GF Value